Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecularly diagnosed glioblastoma: clinical presentation and outcomes.

Journal of neuro-oncology - 7 Aug 2026

Hounchonou Harold F, Polemikos Manolis, Pirayesh Ariyan, Bajgora Genis, Al-Afif Shadi, Hartmann Christian, Krauss Joachim K

Abstract excerpt

BACKGROUND: The 2021 WHO classification permits diagnosis of glioblastoma in IDH-wildtype diffuse astrocytic tumors with TERT promoter mutation, EGFR amplification, or chromosome 7 gain/10 loss, even without necrosis or microvascular proliferation. The clinical behavior of these molecularly defined glioblastomas (molGBM) remains uncertain. METHODS: We retrospectively analyzed patients with molGBM treated at...

Topics

Join the communities discussing this publication.

Biomarkers, Tumor
Brain Neoplasms
Follow-Up Studies
Glioblastoma
Isocitrate Dehydrogenase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed Open full text

Identifiers

PMID: 42567974
DOI: 10.1007/s11060-026-05752-8
PMCID: PMC13451371

Genes

EGFR
TERT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecularly diagnosed glioblastoma: clinical presentation and outcomes.PMID 42567974Read ↗

The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study.Semantic proximity Read ↗

Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of central nervous system tumorsSemantic proximity Read ↗

Clinicoradiological differentiation of TERT promoter-mutant molecular glioblastoma versus histological glioblastoma: a single-center cohort study of 105 IDH-wildtype tumors.Semantic proximity Read ↗

Comparison between molecular and histological IDH-wild-type glioblastoma and extensive subgroup analysis of IDH-wild-type astrocytic tumors without genomic glioblastoma-defining alterations.Semantic proximity Read ↗

Comparative analysis of molecular and histological glioblastomas: insights into prognostic variance.Semantic proximity Read ↗

Molecular GBM versus Histopathological GBM: Radiology-Pathology-Genetic Correlation and the New WHO 2021 Definition of Glioblastoma.Semantic proximity Read ↗

Histopathological and molecular characteristics of IDH-wildtype glioblastoma without contrast enhancement: Implications for clinical outcomes.Semantic proximity Read ↗

IDH wild-type lower-grade gliomas with glioblastoma molecular features: a systematic review and meta-analysis.Semantic proximity Read ↗

Glioblastoma: Changing concepts in the WHO CNS5 classification.Semantic proximity Read ↗

Clinical characteristics and radiological features of glioblastoma, IDH-wildtype, grade 4 with histologically lower-grade gliomas.Semantic proximity Read ↗

Clinical features, MRI, molecular alternations, and prognosis of astrocytoma based on WHO 2021 classification of central nervous system tumors: A single-center retrospective study.Semantic proximity Read ↗

Opinion & Special Article: Glioma Classification: How to Interpret Molecular Markers in a Diffuse Glioma Pathology Report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.